Abstract 2270P
Background
Pancreatic Adenocarcinoma (PAAD) is a highly fatal disease and often associated with a poor prognosis. The development of diabetes mellitus (DM) is an important risk factor. There have been studies exploring markers or prognostic models that affect the prognosis of patients with pancreatic cancer, but there are few studies on pancreatic cancer-associated diabetes mellitus (PCDM) patients.
Methods
The differentially expressed genes (DEGs) between DM and non-DM were detected and selected to build model. PCDM patients were randomly divided into training (70%) and test cohort (30%). Then the univariate COX was performed to screen OS associated genes (p < 0.05) in the training cohort. The LASSO-penalized COX regression and ten-fold cross validation were used to train and select models. The risk score was calculated and verified in both training and test cohort. GSVA, ESTIMATEScore, CIBERSORT and ssGSEA were used to compare the tumor microenvironment (TME). Moreover, the value of genes used in the model was detected on single cell level.
Results
Totally 197 patients (including 60 with DM) were enrolled, 23 genes from DEGs were related to the OS of PCDM patients in the training cohort, and 10 genes were selected to construct the risk model. The risk score for each subject was calculated as follow: risk score=0.434*ACACA+0.119*ATG7+0.373*DEFB123+0.135*FSTL3-0.168*NIPSNAP3B-0.069*RASSF1+0.225*RBPJ+0.364*SLC35F2-0.168*SLC37A1-0.145*ZC3H12D. The C-index was 0.83 in the training cohort (hazard ratio [HR] = 7.61, p < 0.001) and 0.76 in the test cohort (HR = 3.22, p = 0.015). According to the median value -0.054, PCDM patients were split into different risk groups, and patients in the low-risk group showed more enriched T cell related pathways (60 vs 1), higher ImmuneScore (p < 0.001), and more CD8 positive T cell infiltration (CIBERSORT: p < 0.001; ssGSEA: p < 0.001). We calculated the score of genes used in the model in single cells. Malignant cells with the highest score (top 10%) had enhanced activities of angiogenesis.
Conclusions
The prognostic model showed potential value in predicting the OS of patients with PCDM. Patients with low-risk score had a hotter TME and might benefit from immunotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2252P - KRAS G12C inhibition using MRTX849: A novel radio-sensitizing partner
Presenter: Marina Milic
Session: Poster session 08
2253P - RAS-precision medicine trans-atlantic partnership: Comparative analysis of KRAS codon 12 and 13 mutations in non-small cell lung cancer
Presenter: Helen Adderley
Session: Poster session 08
2254P - Persisting RAS addiction: A therapeutic vulnerability in the context of KRAS G12C inhibitor resistance
Presenter: George Morrissey
Session: Poster session 08
2255P - Clinicogenomic landscapes and hallmarks of KRAS amplification in human cancers
Presenter: Biagio Ricciuti
Session: Poster session 08
2256P - The microenvironment of normal mucosa could predict recurrence in the stage II/III colorectal cancer: Multicenter, multiomics study
Presenter: Yeonghak Bang
Session: Poster session 08
2257P - Stereotactic body radiation therapy and atezolizumab combination: Results of the international multi-centre SABR-PDL1 phase II trial colorectal cohort
Presenter: Antonin Levy
Session: Poster session 08
2258P - Organoids as a biomarker for personalized treatment in metastatic colorectal cancer: Drug screen optimization and correlation with patient response
Presenter: Lidwien Smabers
Session: Poster session 08
2259P - An artificial neural network system to predict the fraction of type I polarized macrophage
Presenter: Tongji Xie
Session: Poster session 08
2260P - Berberine associated to SGLT-2i exerts synergistic cardioprotective effects in cardiac cells exposed to the HER2-blocking agent trastuzumab through pAMPK activation and reduction in Interleukin-6 levels
Presenter: Andrea Paccone
Session: Poster session 08
2261P - A head-to-head comparison for detecting PIK3CA mutations in circulating tumor DNA of advanced HR+/HER2- breast cancer patients
Presenter: Nadia Dandachi
Session: Poster session 08